Key result
Adding IV salbutamol to aminophylline fails to improve FEV1 in COPD but increases heart rate.
RCT (n=8)
Double-blind
Cross-over
Mean Difference: 0.07 (95% CI 0.02–0.12)
p-value: p=not significant
It has been previously shown that inhaled salbutamol (S) and intravenous aminophylline (A) have an additive effect as bronchodilators in patients with chronic obstructive pulmonary disease (COPD). This additive effect could be due to different modes of action or different distributions of drug. In order to investigate the additive effect of S and A when administered by the same route, we studied eight patients 63.4 +/- 1.84 yr of age (mean +/- SEM), with long-standing COPD (FEV1, 0.96 +/- 0.12 L) by giving them intravenous A and S. A double-blind, cross-over study was performed on two separate days by administering either A followed by S or vice versa. Each drug when given alone increased the FEV1 significantly (p less than 0.01). The mean increase was 0.17 +/- 0.06 L (18% of baseline) for S and 0.15 +/- 0.05 L (17% of baseline) for A. The FEV1 increased 0.07 +/- 0.02 L when S was added to A (95% confidence interval, 0.02 to 0.12, 7% of baseline), and when A was added to S 0.05 +/- 0.03 L (95% confidence interval, -0.02 to 0.12, 6% of baseline). Neither change was significant. Heart rate (HR) was increased significantly (p less than 0.01) by S (22 +/- 3.4%), but not by A when it was given first. However, addition of the second drug increased HR significantly (p less than 0.01) from HR with one drug alone; the mean increase was 31 +/- 8.5% of baseline with the addition of S, and 19 +/- 4.06% of baseline with the addition of A.(ABSTRACT TRUNCATED AT 250 WORDS)
No takes yet. Share an insight, caveat, or question.
Georgopoulos et al. (1988) conducted an RCT in Chronic obstructive pulmonary disease (COPD) (n=8). Intravenous salbutamol and aminophylline vs. Single drug administration (salbutamol or aminophylline alone) was evaluated on Increase in FEV1 when salbutamol was added to aminophylline (MD 0.07 L, 95% CI 0.02 to 0.12, p=not significant). Adding intravenous salbutamol to aminophylline in COPD patients did not significantly improve FEV1 (mean increase 0.07 L; 95% CI 0.02-0.12) but significantly increased heart rate (P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: